Cargando…
PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis
Cisplatin-based chemotherapy often results in the development of chemo-resistance when used to treat bladder cancer (BC), which is difficult to overcome. Recent data indicate that pyruvate kinase M2 (PKM2), a glycolytic enzyme for Warburg effect, is strongly upregulated in BC, and contributes to the...
Autores principales: | Wang, Yonggang, Hao, Fangshi, Nan, Yonghao, Qu, Licheng, Na, Wanli, Jia, Chunshu, Chen, Xiaoliang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231221/ https://www.ncbi.nlm.nih.gov/pubmed/30443191 http://dx.doi.org/10.7150/ijbs.27854 |
Ejemplares similares
-
Comprehensive Gene Expression Analysis in NMIBC Using RNA-seq Reveals New Therapy Strategies
por: Chen, Xiaoliang, et al.
Publicado: (2019) -
Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2
por: Liu, Tong, et al.
Publicado: (2020) -
Shikonin ameliorated mice colitis by inhibiting dimerization and tetramerization of PKM2 in macrophages
por: Huang, Baoyuan, et al.
Publicado: (2022) -
Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells
por: WADA, NAOKO, et al.
Publicado: (2014) -
Shikonin Kills Glioma Cells through Necroptosis Mediated by RIP-1
por: Huang, Chuanjiang, et al.
Publicado: (2013)